At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 18 enrolled
Drug / intervention
Zometadrug
Likely dose
Zometa 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
In Brief
A Phase 3 clinical trial evaluating Zometa for Breast Cancer. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in postmenopausal early breast cancer patients receiving additional treatment with non-steroidal aromatase inhibitors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedJul 2008
Primary CompletionMar 2011
TodayJul 2026
First PostedJul 11, 2008
Enrollment StartSep 1, 2005
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18.0 years ago
Interventions
Zometadrug
Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose